Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines

NCT01432158 | Completed Phase 3

• 1 other identifier: 2011/04B
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label phase III clinical trial. The purpose of this trial is to investigate in detail the kinetics of the immune response to Prevenar-13, a pneumococcal conjugate vaccine, compared to Pneumovax-II, a pneumococcal plain polysaccharide vaccine. With their consent, healthy adults (n=2 in each group) aged over 18 years who have not received any pneumococcal vaccine in the past will receive either vaccine at their first visit. Blood will be taken before vaccination and at day 0,1,2,4,6,8,10,12,14,16,18,20,23,26,30,35 as well as 2,6 and 12 months following vaccination. With specific consent, a small volume of blood will be used to store DNA and RNA for analysis of the genetic associations with immune responses and adverse reactions to vaccines as well as the RNA expression following a vaccination. Serum or plasma will be used to assess antibody level and available whole blood will be used for B cell assays and to examine immunoglobulin gene usage in B cells.

Conditions

Pneumococcal Disease

Keywords

Invasive pneumococcal disease

Outcome Measures

Primary Outcomes (1)

• Frequency of serotype-specific B cell subsets determined by FACS.

  To assess and compare the kinetics of serotype-specific B cell subsets following a dose of PCV-13 or PPCV-23 given to healthy adults.

  within first month after vaccination

Secondary Outcomes (1)

• Pneumococcal serotype-specific geometric mean concentrations (GMC)

  within first month after vaccination

Study Arms (2)

PCV-13 group

EXPERIMENTAL

1 dose of Prevenar-13

Biological: Prevenar 13

PPV-23 group

EXPERIMENTAL

1 dose of Pneumovax-II

Biological: Pneumovax II

Interventions

Prevenar 13 BIOLOGICAL

This vaccine will be given to healthy adults without prior pneumococcal vaccination.

PCV-13 group

Pneumovax II BIOLOGICAL

This vaccine will be given to healthy adults without prior pneumococcal vaccination.

PPV-23 group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Above 18 years of age.
• Participant is willing and able to give informed consent for participation after the nature of the study has been explained;
• In good health as determined by:
• medical history
• history-directed physical examination
• clinical judgment of the investigator
• Able (in the Investigators opinion) and willing to comply with all study requirements including be available for all the visits scheduled in the study
• Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

You may not qualify if:

• Have previously received a pneumococcal vaccine
• Have received vaccination with a vaccine containing either CRM197 or diphtheria toxoid within the past 12 months,
• Have had previous ascertained disease caused by C. diphtheriae, or S. pneumoniae in the past 5 years documented in their medical notes
• Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;
• Have a known or suspected autoimmune disease or impairment /alteration of immune function resulting from (for example):
• Receipt of immunostimulants
• Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months or long-term systemic corticosteroid therapy (prednisolone or equivalent for more than two consecutive weeks within the past 3 months).
• Have a suspected or known HIV infection or HIV related disease;
• Have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months
• Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;
• Have any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
• Participation in another clinical trial investigating a vaccine, a drug, a medical device, or a medical procedure
• Pregnancy as confirmed by a positive pregnancy test

Sponsors & Collaborators

• University of Oxford: lead
• Mason Medical Research Trust: collaborator

Study Sites (1)

Oxford Vaccine Group

Oxford, United Kingdom

Location

MeSH Terms

Conditions

Pneumococcal Infections

Interventions

13-valent pneumococcal vaccine

Condition Hierarchy (Ancestors)

Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Officials

• Andrew J Pollard, BSc MBBS PhD MRCP FRCPCH

  Department of Paediatrics, Oxford University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 8, 2011
• First Posted: September 12, 2011
• Study Start: January 1, 2012
• Primary Completion: August 1, 2012
• Last Updated: November 9, 2015

Record last verified: 2015-11

Locations

GB (1)